SynthesisBMC cancer2026
A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This meta-analysis aimed to systematically evaluate the incidence and risk of dizziness associated with novel endocrine therapies (androgen receptor pathway inhibitors, ARPIs) in patients with advanced prostate cancer. A comprehensive literature search was conducted across PubMed, Web of Science, and ClinicalTrials.gov databases. After screening titles/abstracts and full-texts, 4 eligible randomized controlled trials (RCTs) involving 4267 patients were included. Risk of bias assessment was performed using the Cochrane Risk of Bias (RoB 2) tool. Meta-analysis results indicated that ARPI-based therapy was significantly associated with an increased risk of all-grade dizziness (risk ratio [RR] = 1.60, 95% confidence interval [CI]: 1.28-2.00, I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.